ETF Prime ETF Prime: Tom Lydon Talks Pros & Cons of Market Cap Weighting By Aaron NeuwirthSeptember 1, 2021
Innovative ETFs Content Hub Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021
ETF Building Blocks Content Hub Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
ETF Building Blocks Content Hub Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
ETF Building Blocks Content Hub As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Innovative ETFs Content Hub Greater Regulatory Scrutiny Could Weigh on Biotech ETFs By Max ChenMarch 24, 2021
Innovative ETFs Content Hub Illumina Earnings, Forward Guidance Strengthen Biotech ETFs By Max ChenFebruary 12, 2021
Innovative ETFs Content Hub Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug By Max ChenJanuary 29, 2021
ETF Building Blocks Content Hub ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
ETF Building Blocks Content Hub Don’t Miss Out on Rampant Biotech Mergers with the SBIO ETF By Tom LydonJanuary 13, 2021
